927 results on '"Pelton, Stephen I."'
Search Results
52. Differential Occurrence of Streptococcus pneumoniae Serotype 11E Between Asymptomatic Carriage and Invasive Pneumococcal Disease Isolates Reflects a Unique Model of Pathogen Microevolution
53. Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media
54. EDITORIAL COMMENTARY: Conjugate Meningococcal Vaccines: Lifesaving or Inefficient Use or Both—No Easy Answer
55. Immunogenicity and Immunologic Memory after Hepatitis B Virus Booster Vaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy
56. Prevention of Invasive Pneumococcal Disease in HIV-Infected Children: Expanding the Toolbox
57. Increase in the Prevalence of the Newly Discovered Pneumococcal Serotype 6C in the Nasopharynx after Introduction of Pneumococcal Conjugate Vaccine
58. Direct-acting agents cure hepatitis C in children
59. Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C
60. Editorial Commentary: Replacement Pneumococcal Disease in Perspective
61. Clinical and Genetic Perspectives in Primary Immunodeficiency Disorders
62. A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination
63. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: Effectiveness of a 2-dose versus 3-dose primary series
64. Meningococcal Disease Awareness: Clinical and Epidemiological Factors Affecting Prevention and Management in Adolescents
65. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
66. Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: Implications for the conjugate vaccine
67. Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus–Exposed Uninfected Infants: A Randomized Clinical Trial
68. Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
69. Otitis Media
70. A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
71. Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action
72. Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIV
73. 25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
74. 96. Relative Vaccine Effectiveness Against Influenza-Related and Any Respiratory-Related Hospital Encounter During the 2019/20 High Influenza Activity Period: A Comprehensive Real-World Analysis to Compare Quadrivalent Cell-based and Egg-based Influenza Vaccines
75. 1341. Relative Vaccine Effectiveness Against Influenza-related Hospitalizations and Respiratory Events During the 2019/20 Influenza seAson in U.S. Children and Adults. A Real-World Evidence Comparison Between Quadrivalent Cell-based and Egg-based Influenza Vaccines
76. Individual Benefit vs Societal Effect of Antibiotic Prescribing for Preschool Children With Recurrent Wheeze
77. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq
78. Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States
79. Epidemiology, Diagnosis, and Treatment of Serious Pneumococcal Infections in Children
80. Immunogenicity in High-Risk and Immunocompromised Children and Adults
81. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
82. Community-Acquired Pneumonia in Infants: Not Simply an Acute Event with Complete Recovery
83. Hepatocyte-specific mutation of both NF-KB RelA and STAT3 abrogates the acute phase response in mice
84. Direct-acting agents cure hepatitis C in children
85. COVID-19 in kids, pregnant women: What do we know?
86. ACIP and 2014 flu vaccine
87. User-friendly smartphone detection of middle ear fluid
88. Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial
89. Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care
90. Case 27-2006: A 17-year-old boy with fever and lesions in the liver and spleen
91. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018–19 influenza season
92. Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid
93. Neuropsychological functioning and viral load in stable antiretroviral therapy--experienced HIV-infected children
94. 61 - Otitis Externa, Otitis Media, and Mastoiditis
95. Otitis Media
96. Contributors
97. Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in Invasive Disease
98. Radiographic resolution of lymphocytic interstitial pneumonitis (LIP) in children with human immunodeficiency virus (HIV): not a sign of clinical deterioration
99. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens
100. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. (Special Article)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.